155 related articles for article (PubMed ID: 10612500)
1. Physical and biological targeting of radiotherapy.
Joensuu H; Tenhunen M
Acta Oncol; 1999; 38 Suppl 13():75-83. PubMed ID: 10612500
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in radiation therapy.
Gerber DE; Chan TA
Am Fam Physician; 2008 Dec; 78(11):1254-62. PubMed ID: 19069018
[TBL] [Abstract][Full Text] [Related]
3. The current status of targeted radiotherapy in clinical practice.
Gaze MN
Phys Med Biol; 1996 Oct; 41(10):1895-903. PubMed ID: 8912369
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
5. Radiation medicine innovations for the new millenium.
Heron DE; Godette KD; Wynn RA; Arterbery VE; Streeter OA; Roach M; Simpson JR; Blough M; Thomas CR
J Natl Med Assoc; 2003 Jan; 95(1):55-63. PubMed ID: 12656450
[TBL] [Abstract][Full Text] [Related]
6. Technical advances in radiotherapy of head and neck tumors.
Thornton AF; Laramore GE
Hematol Oncol Clin North Am; 1999 Aug; 13(4):811-23. PubMed ID: 10494515
[TBL] [Abstract][Full Text] [Related]
7. [Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond].
Teh BS; Paulino A; Butler EB
Ai Zheng; 2008 Aug; 27(8):885-93. PubMed ID: 18710628
[TBL] [Abstract][Full Text] [Related]
8. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
11. Novel cancer therapies: more efficacy, less toxicity and improved organ preservation.
Joensuu H
Ann Med; 2000 Feb; 32(1):31-3. PubMed ID: 10711575
[TBL] [Abstract][Full Text] [Related]
12. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts.
Sautter-Bihl ML; Wessely R; Bihl H
Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984
[TBL] [Abstract][Full Text] [Related]
13. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Ying Z; Zhang CH; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Mar; 38(3):409-18. PubMed ID: 9074529
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in radiation therapy for head and neck cancer.
Bangalore M; Matthews S; Suntharalingam M
ORL J Otorhinolaryngol Relat Spec; 2007; 69(1):1-12. PubMed ID: 17085946
[TBL] [Abstract][Full Text] [Related]
15. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
17. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
19. Comparison of (125)I stereotactic brachytherapy and LINAC radiosurgery modalities based on physical dose distribution and radiobiological efficacy.
Viola A; Major T; Julow J
Radiat Res; 2006 Jun; 165(6):695-702. PubMed ID: 16802870
[TBL] [Abstract][Full Text] [Related]
20. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
